Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 148

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 9B
Chunk 148
---
ITEM 9B. OTHER INFORMATION

During the three months ended December 31, 2024, no director or officer of the company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as provided below.Name & TitleAction TakenDate AdoptedType of Trading Arrangement (1)Aggregate Number of Shares to be  Sold Pursuant to Trading Arrangement (2)Duration of Trading Arrangement(3)Perry C. SiatisExecutive Vice President,General Counsel and SecretaryAdoption11/19/2024Rule 10b5-1 Trading ArrangementUp to 48,568 Shares to be Sold11/19/2025Timothy J. RichmondExecutive Vice President,Chief Human ResourcesOfficerAdoption11/27/2024Rule 10b5-1 Trading ArrangementUp to 83,887 Shares to be Sold07/01/20251.    Except as indicated by footnote, each trading arrangement marked as a "Rule 10b5-1 Trading Arrangement" is intended to satisfy the affirmative defense of Rule 10b5-1(c), as amended.2.    The number of shares to be sold under each trading arrangement represents the maximum actual number of shares issuable under the applicable performance stock awards. The actual number of shares to be sold under each trading arrangement will depend on the achievement of applicable performance conditions under the performance stock awards and the number of shares withheld to satisfy tax obligations upon the vesting of the awards.3.    Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all sales or (b) the date listed in the table. Each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” only permitted or only permits transactions upon expiration of the applicable mandatory cooling-off period under the Rule.